Amgen's Humira Biosimilar Infringes 61 Patents, AbbVie Says
AbbVie Inc. on Thursday told a Delaware federal court that Amgen Inc. has infringed 61 of its patents by attempting to get approval for a biosimilar of AbbVie's blockbuster immunosuppressant Humira...To view the full article, register now.
Already a subscriber? Click here to view full article